Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | ANPEP | P15144 | 4/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058842 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL489252 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL5691732 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL7805563 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL2252585 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL1154972 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL8607697 | 0.92 | MMP2 (0.40) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL8609251 | 0.92 | MMP2 (0.40) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL25436769 | 0.88 | NR1H2 (0.43) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL19898506 | 0.88 | NR1H2 (0.43) | MMP2ANPEPNR1H2NR1H3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2028151-A | — | — | None | — | — | JP | disclosed |
| EP-4678238-A2 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025262433-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| EP-3752251-B1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| EP-4606377-A2 | NOVEL AMINO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4219478-B1 | METHOD OF PREPARING AMINO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-11 | — | — | EP | disclosed |
| US-12195485-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2025-01-14 | — | — | US | disclosed |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| US-5514701-A | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| US-5317016-A | Pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-05-31 | — | — | US | disclosed |
| US-5264453-A | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0289911-B1 | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| EP-0528678-A1 | A pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| US-5130323-A | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0367130-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4916152-A | THROMBOXANE A2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
| JP-H0228151-A | PYRROLIDINE DERIVATIVE | FUJISAWA PHARMACEUT CO LTD | 1990-01-30 | — | — | JP | disclosed |
| EP-0289911-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | MMP2 3660/4885ANPEP 1608/4885NR1H2 3883/4885 |
| US-12195485-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, PRMT1 | MMP2 1125/4885ANPEP 1813/4885NR1H2 172/4885 |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MMP2 999/4885ANPEP 1703/4885NR1H2 171/4885 |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | MMP2 2585/4885ANPEP 1615/4885NR1H2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.